Post by Maury Krupp, CIM®

The Deal: Bristol Myers Squibb (NYSE:BMY) and MyoKardia Inc.(NASDAQ:MYOK) have announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $225.00 per share in cash. The transaction will provide Bristol Myers Squibb with mavacamten, a potential first-in-class cardiovascular medicine treating hypertrophic cardiomyopathy ("HCM"), chronic heart disease with high morbidity. The Terms: Under the terms of the merger agreement, a subsidiary of Bristol Myers Squibb will tender an offer to acquire all outstanding shares of MyoKardia's common stock for $225.00. Disclosure: Accelerate Arbitrage Fund (TSX: ARB) holds no position in this transaction. "AlphaRank" Deal Sheet: https://lnkd.in/e_ky_8r #mergersandacquisitions #investing #etfs #alternativeinvestments